Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug

被引：86

作者：

De Smedt, Tim ^{[1
]}

Raedt, Robrecht ^{[1
]}

Vonck, Kristl ^{[1
]}

Boon, Paul ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Neurol, Lab Clin & Expt Neurophysiol, Reference Ctr Refractory Epilepsy, B-9000 Ghent, Belgium

来源：

CNS DRUG REVIEWS | 2007年 / 13卷 / 01期

关键词：

anticonvulsants; epilepsy; levetiracetam;

D O I：

10.1111/j.1527-3458.2007.00005.x

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add-on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.

引用

页码：57 / 78

页数：22

共 72 条

[1] Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study [J].

Alsaadi, TM ;

Shatzel, A ;

Marquez, AV ;

Jorgensen, J ;

Farias, S .

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2005, 14 (02) :139-142

[2] Levetiracetam monotherapy for newly diagnosed epilepsy patients [J].

Alsaadi, TM ;

Thieman, C .

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :154-156

[3]

Arroyo S, 2003, EPILEPTIC DISORD, V5, pS57

[4]

ARROYO S, 2004, IUPHAR COMPENDIUM BA, P165

[5] Levetiracetam:: a long-term follow-up study of efficacy and safety [J].

Bauer, J. ;

Ben-Menachem, E. ;

Kraemer, G. ;

Fryze, W. ;

Da Silva, S. ;

Kasteleijn-Nolst Trenite, D. G. A. .

ACTA NEUROLOGICA SCANDINAVICA, 2006, 114 (03) :169-176

[6] Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy [J].

Ben-Menachem, E ;

Falter, T .

EPILEPSIA, 2000, 41 (10) :1276-1283

[7]

Ben-Menachem E, 2003, EPILEPTIC DISORD, V5, pS51

[8] Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy [J].

Ben-Menachem, E ;

Edrich, P ;

Van Vleymen, B ;

Sander, JWA ;

Schmidt, B .

EPILEPSY RESEARCH, 2003, 53 (1-2) :57-64

[9]

BENMENACHEM E, 2006, AM AC NEUR APR 2006

[10] Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs [J].

Bergey, GK .

EPILEPSIA, 2005, 46 :161-168

← 1 2 3 4 5 6 7 8 →